Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So
Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.
You may also be interested in...
Novartis' half-year results show eye business Alcon and heart drug Entresto - which have been the two main sources of concern - are finally turning around, and its pipeline is firing on all cylinders towards a post-Gleevec recovery.
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.
Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.